Sampeginterferon beta-1a in clinical practice

Abstract

In multiple sclerosis (MS), the development and introduction of disease-modifying treatments (DMTs) into clinical practice can improve treatment outcomes. Interferon beta drugs are commonly used as DMTs. Among these drugs, sampeginterferon beta-1a (Tenexia®) was recently approved – an innovative original development of BIOCAD that is the next pegylated interferon beta-1a in its class. Clinical observations of patients with relapsing-remitting MS who received Tenexia® are presented. In the first clinical observation, the patient initially received glatiramer acetate as DMT, which led to exacerbations and an increase in neurological disturbances. The patient was switched to treatment with Tenexia®, during which no exacerbations and no increase in neurological disturbances were observed. In the second observation, the patient, who had been suffering from MS for 11 years, did not receive any DMTs. A year ago, the drug Tenexia® was prescribed as a DMT for the first time, with no exacerbations, no increase in neurological disturbances or negative changes on MRI during treatment. In the third observation, a patient suffering from MS for 5 years was initially prescribed teriflunomide as DMT, with exacerbations and an increase in neurological disturbances noted during the treatment. The patient was switched to Tenexia®, which led to a stable remission. The presented observations reflect the positive experience with the use of the drug sampeginterferon beta-1a in real-life clinical practice.